Fibrocell Science Inc (FCSC)
(Delayed Data from NSDQ)
$2.24 USD
+0.02 (0.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.24 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[FCSC]
Reports for Purchase
Showing records 1 - 20 ( 135 total )
Industry: Medical - Biomedical and Genetics
Price: 25.00
Industry: Medical - Biomedical and Genetics
Fibrocell Acquired by Partner Castle Creek; Downgrade to Neutral and Lowering Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
2Q19 Results; FCX-007 Officially Pivotal; DEFI-RDEB has Started; Adjusting Target to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
Another Nice Feather in the FCX-007 Cap With RMAT Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
1Q19 Results; About to Press Accelerator on Pivotal Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
Timely, Strategic, and Validating Partnership for FCX-007; Phase 3 Starting Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
Visibility Is Priceless; FDA Feedback and Continuing Positive Data Drive Thesis Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
3Q18 Results- FDA Seems Raring to Go; FCX-007 Going Pivotal Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
We are Suspending Coverage on the following companies due to analyst transition
Provider: Griffin Securities, Inc.
Price: 25.00
Industry: Medical - Biomedical and Genetics
2Q18 Results; FCX-007 Phase 2 Portion Hitting its Stride; Looking Forward to FDA Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
A Gene, Wound Healing, and Immunohistochemistry, Oh My; Reiterate Buy on Value Disconnect; Split-Adjusted Target to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
1Q18 Results; We Can''t Wait to See the May 19 Update for FCX-007
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
We See Tipping Point Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
FCX-013 IND Cleared as Fibrocell''s Second Clinical Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
Important Nod From FDA to Move Into Kids; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 10.00
Industry: Medical - Biomedical and Genetics
FDA Visibility Key as Pivotal Study Not Too Far Off; Reiterate Buy and Target Adjusted to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
Healing What Was Unhealable; Further Insight Into FCX-007 Proof-of-Concept RDEB Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
Price: 25.00
Industry: Medical - Biomedical and Genetics
Nice First Look; Important Proof-of-Concept Now In Hand; Await FDA for Next Steps; Target Increased to $7.60
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Industry: Medical - Biomedical and Genetics
RDEB Data Imminent; Management Update Focuses on Getting to FDA Asap
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 10.00